P. Rutgeerts

Publications398
h-index75
Citations32,585
Highly Influential Citations1,042
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • W. Sandborn
  • 1,901 Publications, 94,323 Citations
  • B. Feagan
  • 817 Publications, 46,011 Citations
  • S. Vermeire
  • 670 Publications, 36,408 Citations
  • P. Rutgeerts
  • 889 Publications, 29,314 Citations
  • Publications
  • Influence
Infliximab for induction and maintenance therapy for ulcerative colitis.
BACKGROUND Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis. METHODS Two… Expand
  • 2,244
  • 75
  • PDF
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
BACKGROUND Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical… Expand
  • 1,847
  • 71
Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test.
BACKGROUND The aim of the present study was to develop a breath test for measuring gastric emptying rate of solids that would induce less radiation exposure than radioscintigraphy and would be… Expand
  • 829
  • 63
Vedolizumab as induction and maintenance therapy for Crohn's disease.
BACKGROUND The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown. METHODS In an integrated study with separate induction and maintenance trials, we assessed… Expand
  • 1,382
  • 56
  • PDF
Predictability of the postoperative course of Crohn's disease.
Eighty-nine patients who had been treated by ileal resection for Crohn's disease between 1979 and 1984 were included in a prospective cohort follow up to study the natural course of early… Expand
  • 1,353
  • 51
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
BACKGROUND Studies in animals and an open-label trial have suggested a role for antibodies to tumor necrosis factor alpha, specifically chimeric monoclonal antibody cA2, in the treatment of Crohn's… Expand
  • 1,292
  • 51
Infliximab for the treatment of fistulas in patients with Crohn's disease.
BACKGROUND Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor alpha, has recently… Expand
  • 1,926
  • 42
  • PDF
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
Genome-wide association studies and candidate gene studies in ulcerative colitis have identified 18 susceptibility loci. We conducted a meta-analysis of six ulcerative colitis genome-wide association… Expand
  • 1,204
  • 39
  • PDF
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
BACKGROUND & AIMS Infliximab, an anti-tumor necrosis factor monoclonal antibody, rapidly reduces signs and symptoms of active Crohn's disease. The aim of this study was to determine whether repeated… Expand
  • 1,031
  • 28
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
BACKGROUND Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely… Expand
  • 423
  • 27
  • PDF